Brian Henick, MD

Trials

Studies that name Brian Henick, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:44 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT06673329 · Brodalumab in the Treatment of Immune-Related Adverse Events

  Brian Henick, MD · recruiting · Breast Cancer, Esophageal Cancer, Kidney Cancer · principal investigator
• N/A
  NCT05812274 · Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients

  Columbia University · terminated · Non Small Cell Lung Cancer · principal investigator
• Ph2
  NCT04923776 · Liver Directed RT + Chemo-immunotherapy for ES-SCLC

  Brian Henick, MD · terminated · Small-cell Lung Cancer · principal investigator
• N/A
  NCT04791215 · Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With Pembrolizumab

  Columbia University · terminated · Non Small Cell Lung Cancer · principal investigator
• N/A
  NCT04571398 · A Study of ApricityRx™ for Management of IR-AEs in Patients on Immuno-Oncology Therapy

  Apricity Health, Inc · unknown · Cancer · principal investigator
• Ph2
  NCT04375228 · Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)

  Columbia University · active not recruiting · Immune-related Adverse Events, Advanced Solid Tumor · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 06:44 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.